Cargando…

Pharmacokinetic Analysis of (111)In-Labeled Liposomal Doxorubicin in Murine Glioblastoma after Blood-Brain Barrier Disruption by Focused Ultrasound

The goal of this study was to evaluate the pharmacokinetics of targeted and untargeted (111)In-doxorubicin liposomes after these have been intravenously administrated to tumor-bearing mice in the presence of blood-brain barrier disruption (BBB-D) induced by focused ultrasound (FUS). An intracranial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Feng-Yi, Wang, Hsin-Ell, Liu, Ren-Shyan, Teng, Ming-Che, Li, Jia-Je, Lu, Maggie, Wei, Ming-Cheng, Wong, Tai-Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445513/ https://www.ncbi.nlm.nih.gov/pubmed/23029030 http://dx.doi.org/10.1371/journal.pone.0045468

Ejemplares similares

Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound
por: Yang, Feng-Yi, et al.
Publicado: (2012)

Pharmacokinetics of a liposomal formulation of doxorubicin in rats
por: Liu, Zongyu, et al.
Publicado: (2017)

(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Reply: (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Koukourakis, M I
Publicado: (2002)

Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats
por: Lee, Wen-Chuan, et al.
Publicado: (2012)

Biodistribution and pharmacokinetics of(111)In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies
por: Harrington, K J, et al.
Publicado: (2000)

Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes
por: Hsieh, Yuan-Chin, et al.
Publicado: (2018)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000)

Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
por: Lin, Yi-Yu, et al.
Publicado: (2013)

Pharmacokinetics, Tissue Distribution and Therapeutic Effect of Cationic Thermosensitive Liposomal Doxorubicin Upon Mild Hyperthermia
por: Dicheva, Bilyana M., et al.
Publicado: (2015)

Influence of tumour size on uptake of(111)In-DTPA-labelled pegylated liposomes in a human tumour xenograft model
por: Harrington, K J, et al.
Publicado: (2000)

Immunoscintigraphy and Pharmacokinetics of Indium‐111‐labeled ZME‐018 Monoclonal Antibody in Patients with Malignant Melanoma
por: Koizumi, Mitsuru, et al.
Publicado: (1988)

Multiple sessions of liposomal doxorubicin and focused ultrasound mediated blood-brain barrier disruption: safety study
por: Aryal, Muna, et al.
Publicado: (2015)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Guidelines for the labelling of leucocytes with (111)In-oxine
por: Roca, Manel, et al.
Publicado: (2010)

Preparation, In-Vitro Characterization and Pharmacokinetic Evaluation of Brij Decorated Doxorubicin Liposomes as a Potential Nanocarrier for Cancer Therapy
por: Fazel, Mohammadtaghi, et al.
Publicado: (2018)

Preparation and Evaluation of Thermosensitive Liposomes Encapsulating I-125-Labeled Doxorubicin Derivatives for Auger Electron Therapy
por: Elghobary, Mohamed Elsaid Nasr, et al.
Publicado: (2023)

Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics
por: Taiarol, Lorenzo, et al.
Publicado: (2022)

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022)

Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model
por: Lin, Liang-Ting, et al.
Publicado: (2016)

Ultrasound-triggered tumor therapy with doxorubicin-liposome-microbubble complexes in a subcutaneous murine colon adenocarcinoma model
por: Klibanov, Alexander, et al.
Publicado: (2015)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome
por: Yadav, Nidhi, et al.
Publicado: (2015)

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes
por: Mehn, Dora, et al.
Publicado: (2017)

Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
por: Aloss, Kenan, et al.
Publicado: (2023)

Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
por: Rahman, A., et al.
Publicado: (1986)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Reversible Electroporation–Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With (89)Zr-Labeled Reporter Nanoparticles
por: Srimathveeravalli, Govindarajan, et al.
Publicado: (2018)

Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma
por: Chen, Qi, et al.
Publicado: (2019)

Erratum to: Guidelines for the labelling of leucocytes with (111)In-oxine
por: Roca, Manel, et al.
Publicado: (2010)

Development of (111)In-labeled porphyrins for SPECT imaging
por: Sadeghi, Shaghayegh, et al.
Publicado: (2014)

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma
por: Chan, Hui-Wen, et al.
Publicado: (2022)

Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model
por: Maswadeh, Hamzah M, et al.
Publicado: (2015)

Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_3epcokn2nkvasd0nqru86r5sh2